MindMed: Pipeline
MindMed has a pretty comprehensive pipeline of drugs they are developing. This pipeline has started to expand more due to their partnerships and acquisitions. Through their partnerships with labs, universities, and researchers, MindMed has exclusive licenses, including DMT, MDMA, LSD, Psilocybin. There are currently four trials going on at University Hospital Basel, and 13 have already been completed giving MindMed some very valuable data to help push their approvals and research along with faster than they otherwise could have. Here’s an overview of their programs, compounds, and trials, along with their stage of development.
Discover:
April 2020, MindMed signed a nice exclusive collaboration deal with University Hospital Basel’s Liechti Lab (some of the most prolific psychedelic researchers). All IP, trial data, and tech that’s developed here are MindMed’s for the foreseeable future. This originally only gave them access to LSD trials and data, but they’ve since upped their game and expanded the deal to include trials and data on MDMA, DMT, MDMA-LSD (candy flipping), and Psilocybin. Any solid discoveries or advancements will be integrated into MindMed’s pipeline. For example, MindMed already gained data from an ongoing P2 LSD-Anxiety trial from UHB.
February 11, 2021, MindMed announced a partnership with MindShift out of Switzerland. This partnership is focused more on developing novel psychedelic compounds to add to their pipeline. This has been a huge trend in the sector. Companies are trying to modify the compounds to be more conducive to the therapeutic process. Lots of talks have been had around taking the “trip” out of the trip. They are basically allowing people to feel the benefits without hallucinating. Their CEO said some compounds have already been identified for development, but there’s not much on what exactly these secret compounds are. However, patents have apparently been filed over these compounds, so if any of you sleuths can find them, it would be much appreciated.
Develop:
Once psychedelic compounds are identified, they’ll move onto this stage. As of now MindMed has a couple big ones in the works which you’ll be able to find more details on in the chart below. The trials of focus right now investigating 18-MC and LSD for different purposes.
Company / Partner Compound Disorder / Purpose Progress / Stage Rights / IP / Data Market Competition
MindMed (Project Layla) 18-MC (ibogaine derivative) Opioid Use Disorder, Withdrawal, and Potentially Other Addictions P2a (Q3 2021) P3 (at the earliest 2023) Provisional patent filings (MindMed Assignee) ATAI has partnered with DemeRX who are working on Ibogaine and Noribogaine therapy for opioid use disorder and are slightly ahead of MMED. Awakn and CYBN are also both looking at compounds for alcoholism.
MindMed (Project Lucy) LSD Anxiety P2b (Second half of 2021) UHB Data Diamond Therapeutics is working on treating anxiety with psilocybin.
MindMed (UHB) Ketanserin Psychedelic Antagonist (The Naloxone of Psychs) P1 (ongoing) MindMed + UHB have filed a patent application preserving worldwide rights Benzos have been used to kill trips so plenty of people say this isn't needed (I disagree)
MindMed (UHB) LSD LSD Cluster Headaches P2 (ongoing) UHB Data and Rights Beckley Psytech is working on similar headache attacks
MindMed (Project Flow) LSD Adult ADD P2a (approval granted Q3 2021) UHB Data and Rights No ongoing trials in other companies investigating this
MindMed LSD Microdosing (focus, creativity, mood, anxiety) (Starting soon) Honestly don't know First ever P2a clinical trial for microdosing LSD. Very little competition this far along
MindMed (UHB) DMT Neurodynamics P1 (Q2 2021) UHB Data and Rights Algernon is looking at DMT for stroke rehabilitation
MindMed (UHB) LSD + MDMA Candy flipping Investigation P1 (Q1 2021) UHB Data and Rights No candy flipping trials have been conducted yet
MindMed (MindShift) Novel Compounds Investigative Launching early (Q1 2022) Patents filed preserving rights to the novel compounds CYBN is likely one of MMED's biggest competitors in this space. They are killing it in the novel compound development.
MindMed has some additional compounds that they plan to develop that there hasn’t been a ton of information posted on. However, they are the assignee of a family of patents in the US, Australia, Canada, Europe, Japan, and New Zealand for psychotherapy using 3-MMC. The disorders it covers are distress, PTSD, generalized anxiety disorder. A lot of other MindMed IP is being held as trade secrets for the time being, so there’s not a lot to say about it at the moment other than they are expanding their pipeline significantly.
News 
Market Data 
Discover 
AI
